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STRUCTURED ABSTRACT  
 
Background: Colorectal cancer (CRC) is the third most common cancer 
worldwide. Age is the strongest non-modifiable risk factor but it is estimated 
that over half of CRC cases are linked with lifestyle factors such as diet. The 
Biomarkers Of RIsk of Colorectal Cancer (BORICC) Study recruited 363 
participants in 2005 to investigate the effects of lifestyle factors on biomarkers 
of CRC risk.  
Aim: In the present BORICC Follow-Up (BFU) Study, we are using a 
longitudinal study design to investigate the effects of ageing (12+ years) and 
lifestyle factors on biomarkers of CRC risk and on healthy ageing. 
Methods: Forty-seven of the original BORICC participants were re-recruited to 
the BFU Study (mean age 67 years, 51% female). Participants attended a study 
visit at North Tyneside General Hospital (UK) for collection of biological 
samples, including blood and rectal biopsies, and information collected 
included anthropometric measurements, a Health & Medications 
Questionnaire, physical activity and sedentary behaviour and habitual diet. 
Furthermore, musculoskeletal function was assessed by heel bone 
densitometry, timed up and go and hand grip strength as markers of healthy 
ageing. The BFU Study outcomes will be similar to those measured at baseline 
in the BORICC Study, such as DNA methylation and mitochondrial function, 
with additional measurements including the gut microbiome, faecal short-chain 
fatty acid concentrations and expression of genes associated with CRC.  
Summary: Ultimately, identifying lifestyle factors that can reduce CRC risk, and 
understanding the underlying mechanisms for the effects of lifestyle and ageing 
on CRC risk which could lead to early prevention strategies. 
INTRODUCTION 
Colorectal cancer (CRC) is the third most common cancer worldwide and fourth 
most common cause of cancer-related death. Older age is the strongest risk 
factor for CRC and risk increases exponentially after the age of 50. In the UK, 
between 2013 and 2015, 44% of CRC cases were diagnosed in people aged 
≥75 years and the highest incidence rates were in individuals aged 85-89 years. 
Up to 15% of CRCs are inherited with the majority (>85%) occurring 
sporadically. CRC risk is also modified by environmental and lifestyle factors, 
notably diet and physical activity, and it is estimated that 54% of CRC cases in 
the UK are preventable (Brown et al., 2018). It is therefore important to 
determine which lifestyle factors have chemoprotective properties or are 
associated with an increased risk of CRC and to understand the mechanisms 
by which they modulate CRC risk. For example, obesity, high intake of red and 
processed meat and high levels of sedentary behaviour increase CRC risk, 
whereas higher intakes of dietary fibre and high levels of physical activity are 
protective (WCRF/AICR, 2018). The mechanisms through which lifestyle 
factors modulate CRC risk include genomic damage caused by inflammation, 
oxidative stress and metabolic stress which may result in increased cell 
proliferation and reduced apoptosis. In particular, adverse dietary factors may 
dysregulate gene expression (increased expression of oncogenes and reduced 
expression of tumour suppressor genes) through epigenetic mechanisms 
including DNA methylation, histone modifications, changes in chromatin 
structure and altered patterns of expression of non-coding RNA e.g. microRNA 
(miRNA).  
 
The Biomarkers Of RIsk of Colorectal Cancer (BORICC) Study recruited 363 
patients attending Wansbeck General Hospital, Northumberland, UK for 
diagnostic endoscopy (flexible sigmoidoscopy or colonoscopy) in 2005. Of 
these, 262 patients with no detectable large bowel pathology were recruited to 
the ‘healthy’ arm of the study (BORICC 1) whilst 101 patients with adenomatous 
polyps were recruited to the ‘polyp’ arm (BORICC 2). The aim of the study was 
to identify and validate potential biomarkers of CRC risk. The BORICC Study 
investigated effects of lifestyle factors, particularly diet and adiposity, and age 
on biomarkers of CRC risk, with a focus on DNA methylation (Tapp et al., 2013). 
At baseline, age was a major determinant of gene-specific methylation levels 
(Tapp et al., 2013). In addition folate status (plasma folate and red cell folate), 
plasma 25-hydroxyvitamin D and plasma selenium and waist and hip 
circumferences were associated with both gene-specific, e.g. WIF-1 and 
SFRP1, and global (LINE-1) DNA methylation levels (Tapp et al., 2013). These 
findings suggested that these nutrition-related factors modulate methylation 
patterns in the colorectal mucosa of healthy individuals and that effects on DNA 
methylation may be a potential mechanism for the modulation of CRC risk by 
lifestyle factors. In addition, low selenium status was associated with aberrant 
gene expression detectable at mRNA and protein levels in the colorectal 
mucosa, including genes implicated in cancer, cell growth and proliferation, cell 
death and the inflammatory response (Meplan et al., 2016). Using BORICC 
Study samples, we also observed that clonal expansion of mitochondrial DNA 
mutations is the main mechanism causing age-related mitochondrial 
dysfunction in the apparently-healthy colorectal epithelium (Greaves et al., 
2014). 
 The aim of the BFU Study is to investigate the effects of increasing age, as well 
as lifestyle factors notably diet, adiposity, physical activity and sedentary 
behaviour, on biomarkers of large bowel health and CRC risk. In addition, we 
aim to investigate the effects of change in lifestyle factors over 12+ years on 
markers of healthy ageing, large bowel health and CRC risk. 
 
We hypothesise that i) biomarkers of CRC risk worsen with age and ii) higher 
risk lifestyles, including unhealthy dietary patterns, higher adiposity and low 
physical activity, exacerbate this age-related increase in risk. This project aims 
to test these hypotheses by examining differences in biomarkers of CRC risk 
cross-sectionally and by determining changes in these biomarkers 
longitudinally (after 12+ years) in BFU Study participants. 
 
METHODS 
Study design 
The BFU Study is a longitudinal 12+ years follow-up of participants in the 
BORICC Study (recruited in 2005) that investigated the effects of lifestyle on 
biomarkers of bowel cancer risk. The BFU Study will investigate the effects of 
ageing (12+ years) on these biomarkers. Longitudinally, we will investigate how 
lifestyle factors at baseline impact on biomarkers of bowel cancer risk 12+ years 
later, and how change in lifestyle factors (e.g. increased adiposity or change in 
diet) influence these biomarkers. Cross-sectionally, we will investigate 
associations between current lifestyle factors and CRC-related biomarkers. The 
trial is registered at ClinicalTrials.gov (ClinicalTrials.gov Identifier: 
NCT04005742). 
 
Study size 
To provide an estimate of the numbers of participants that we would need to 
re-recruit, we used data for differences in our primary outcome faecal 
calprotectin (FCP) concentration between participants who differed in mean 
age by 10 years at baseline for a power calculation. Using an alpha of 0.05 for 
2-sided tests, mean FCP concentrations of 11.0 and 16.7 mg/kg for the younger 
and older groups (differing in mean age by 10 years) respectively and a 
standard deviation for the whole population of 10.4, showed that we required 
53 participants (power of test = 0.8).   
 
Ethical approval  
Ethical approval for the BFU Study was granted by the West Midlands - 
Coventry & Warwickshire Research Ethics Committee on 29th November 2016 
(REC No. 16/WM/0424). Two amendments were made to the study; the first to 
include a response card and invite potential participants to Showcase events 
described below (approved May 2017) and the second to call any participants 
not returning their response cards to check whether they had received the study 
invitation letter (approved December 2017). Caldicott approval for the storage 
of data was provided by the Northumbria NHS Foundation Trust.   
 
Participant recruitment 
Participants who took part in the BORICC Study at baseline were invited to 
participate in the BFU Study. Exclusion criteria included not being able to 
provide informed written consent or not being able to travel to attend the 
hospital study visit. Participants on anticoagulant medication that may increase 
their risk of bleeding during rigid sigmoidoscopy were invited to participate in all 
aspects of the study except the collection of rectal mucosal biopsies. Participant 
recruitment started in March 2017 and ended in June 2018. The steps taken to 
recruit participants to the BFU Study are summarised in Figure 1. 
 
Invitation letter 
An invitation letter, information leaflet explaining the study, a flyer advertising 
BFU Study Showcase events (please see following section) and a response 
card with a stamped and addressed envelope were sent to potential 
participants in batches of 60 invitations. If no response was received within 3 
weeks, a second invitation letter was posted. Participants were asked to return 
their response cards to the research team by ticking one of four possible 
responses: 
• Yes, I am interested in attending the BFU Study Showcase Event on ___ 
• Yes, I am interested in attending the BFU Study Showcase Event however 
these dates are not suitable for me 
• Yes, I am interested in taking part in the BFU Study but I prefer not to 
attend a Showcase Event 
• No, I am not interested in taking part in the BFU Study and I do not want 
to be contacted again by the research team 
 
Those interested in taking part in the study were asked to contact the research 
team by telephone, email or post. If a participant responded saying that they 
would like to attend a Showcase event, a suitable date and time was arranged 
and a letter was posted to them with directions to the North Tyneside General 
Hospital Education Centre.  
 
Study Pack 
Study packs were posted to participants approximately two weeks before their 
arranged study visit date. This was to allow participants sufficient time to wear 
the accelerometer for a week before the visit, to complete the questionnaires 
and to collect urine and stool samples.  
The study packs contained a folder including: 
• Study pack instructions 
• Consent forms  
• Hospital study visit instructions and directions 
• Food frequency questionnaire (FFQ) 
• Lifestyle questionnaire 
• Sunlight exposure questionnaire 
• Accelerometer instructions, record sheet and sleep log 
• Stool collection instructions 
• Urine collection instructions 
• At-Home sample and questionnaire collection record sheet 
 
The following were also included in the study pack: 
• Accelerometer (GENEActiv™) 
• Stool collection pot (Fecotainer®) 
• Cool bag and block for transportation of samples 
• Urine collection pots x 2 
• Urine vacutainers x 8 separated into two zip lock bags  
 
Food Frequency Questionnaire 
Participants completed a food frequency questionnaire (FFQ) that was adapted 
from that used in the EPIC Study (Bingham et al., 1997; Kroke et al., 1999). 
Details of adaptations are provided in Supplementary Material. 
 
Physical activity and sedentary behaviour 
Physical activity and sedentary behaviour were assessed subjectively via a 
self-reported lifestyle questionnaire used previously in the EPIC Study (Cust et 
al., 2008) and used in the BORICC Study at baseline. This was extended to 
collect information on sedentary behaviour using the LASA (Longitudinal Aging 
Study Amsterdam) sedentary behaviour questionnaire (Visser and Koster, 
2013). 
 
Physical activity and sedentary behaviour were also assessed objectively using 
the GENEActiv™ accelerometer. Participants were asked to wear the 
accelerometer on their non-dominant hand, continuously, for 7 days prior to 
their study visit. Sleep logs were used to determine sleep and non-sleep times 
for participants and to identify shift workers. An accelerometer record sheet was 
also completed to record any periods of time when the accelerometer was 
removed.  
 Sunlight exposure questionnaire 
Habitual sunlight exposure including day-to-day sun exposure and sun 
exposure during holidays was assessed using an adapted questionnaire 
(Cashman et al., 2008). This sunlight exposure questionnaire has been used 
previously to determine the effect of sunlight exposure on nutritional 
requirements for vitamin D with good predictability. 
 
Urine and stool sample collection 
Equipment for the collection of urine and stool at home were included in the 
study packs posted to participants. Participants were asked to collect two urine 
samples, one on a weekend day and one on a weekday. Mid-stream urine 
specimens were collected in a sample collection container and transferred to 4 
vacutainer tubes which were stored in the fridge. Stool samples were collected 
in a Fecotainer® (AT Medical, The Netherlands). Participants were asked to 
collect their stool samples on the day of, or the day before, their study visit. 
Participants recorded the date and time the urine and faeces samples were 
collected and brought these to their study visit in the cool bags provided. The 
stool samples were homogenised by mashing in a strong, zip-lock bag and 
aliquoted using sterile plastic spatulas into five bijou tubes. Urine and stool 
samples were stored at -80°C. 
 
Figure 1: Schematic of participant recruitment to the BFU Study 
 
Study visit 
Study visits, lasting approximately 45 minutes (30 minutes if rectal mucosal 
biopsies were not collected), were carried out at North Tyneside General 
Hospital (UK). Consent forms were counter-signed by a member of the 
research team, questionnaires and paperwork were checked to ensure 
completion and the accelerometers were collected. Anthropometric measures 
(described below) and three musculoskeletal function tests (heel bone 
densitometry, hand grip strength and timed up and go test) were performed. A 
clinical member of the research team (AJ or KEG) completed the Health & 
Medications Questionnaire and described the clinical procedures (buccal cell 
swabs, blood samples and collection of rectal biopsies) to be made. In the 
clinical sample room, samples were collected in the order blood samples, 
buccal cell sample and rectal mucosal biopsies. 
 
Anthropometric Measurements 
Height was measured using a Leicester stadiometer (Seca) in the Frankfurt 
Plane and Tanita digital scales (Tanita Europe B.V., The Netherlands) were 
used to measure body mass, body fat percentage and body mass index (BMI). 
Waist and hip circumferences were measured as described by Marfell-Jones, 
Olds et al. (2006). All measurements were performed twice or repeated until 
within 0.1cm for height, 0.1kg for weight and 1cm for waist and hip 
circumferences. The mean of the two closest measurements was used for 
further analyses.  
 
Heel bone densitometry  
Heel bone density was measured using the Achilles heel ultrasound device GE 
AchillesTM EXPII ultrasonometer) in compliance with the product manual 
guidelines. Participants were asked to remove their shoes and socks and sit on 
a chair. Participants placed one foot in the footplace of the instrument making 
sure the heel was as far back as possible and the calf was resting on the calf 
rest. Participant details were entered onto the machine (participant ID, age, 
gender). Membranes of the heel ultrasound device and either side of the heel 
were sprayed with ethanol solution. The membranes were sprayed with 70% 
ethanol and the measurement was made. The measurement was made twice 
for both heels and an average calculated for each heel. Calibration and quality 
control tests were completed prior to each participant using a phantom. 
 
Hand grip strength  
Hand grip strength was measured with a Jamar dynamometer. The participant’s 
dominant hand was recorded as well as any problems or pain in their arms or 
hands. Participants sat on a chair with an armrest and rested one forearm on 
the armrest, with the elbow bent at a 90° angle. Three measurements were 
made per arm, following a practice measurement. 
 
Timed up and go test  
Prior to starting, participants were asked if they suffered from any lower body 
problems or pain. Participants were asked to sit on a chair and, when instructed, 
to stand up, without help from arms or leaping, and to walk 3 metres to a floor 
marker at a comfortable speed without running, turning, walking back to the 
chair and sitting down, again without jumping or helping with their arms. The 
timer was started as soon as the participants were instructed to ‘go’ and 
stopped as soon as the participant sat down. The test was repeated three times 
with a 30 second break between tests.  
 
Biological sample collection: 
 
Buccal cell swabs 
Participants were asked to swab up and down the inside of their cheeks firmly 
with the buccal swab (SK-2S DNA buccal swabs (Isohelix™, UK)) for one 
minute. Swabs were placed immediately in the 2ml collection tube and 500µl 
BuccalFix stabilisation buffer (Isohelix™, UK) were added. 
 
Blood sample collection 
Blood samples were collected in four 5ml BD Vacutainer® SST™ II Advance 
tubes with gold hemogard closure (Becton Dickinson, UK), two 4ml BD 
Vacutainer® K3EDTA tubes (Becton Dickinson, UK) and one 5ml 
fluoride/oxalate tube. An aliquot of whole blood from a K3EDTA tube was 
separated to be sent for analysis of HbA1c concentration. Vacutainers were 
centrifuged at 7,000 rpm for 10 minutes immediately after collection. Serum and 
plasma were aspirated and divided into 500μl aliquots in 1.5ml centrifuge tubes. 
After aspiration of serum from the BD Vacutainer® SST™ II Advance tube with 
gold hemogard closure tubes, white blood cells were removed using a Pasteur 
pipette and aliquoted into four separate 1.5ml centrifuge tubes. Aliquots of 
whole blood, plasma and serum were sent immediately to North Tyneside 
General Hospital laboratories for analysis of HbA1c, glucose and lipids, 
respectively. Serum aliquots were sent to the Newcastle Laboratories (Royal 
Victoria Infirmary and Freeman Hospital, Newcastle) for analysis of high-
sensitivity C-reactive protein (hsCRP), folate, vitamin B12, vitamin D (total 
25(OH)D) and parathyroid hormone (PTH)). The remaining samples were 
frozen immediately and stored at -80°C for subsequent analyses.  
 
Human colorectal tissue samples 
Ten biopsies were taken from the mid-rectum (10cm from the ano-rectal verge) 
from the apparently-normal, healthy mucosa using Sarratt biopsy forceps 
(Stericom, 2.3mm diameter, smooth without spike REF STE1500). No bowel 
preparation was used.  Following the rigid sigmoidoscopy procedure, 
participants were given an aftercare advice information sheet. Ten 
circumferential biopsies were taken from each participant and were processed 
as detailed in Table 1. Snap-frozen biopsies and those in RNAlater® were 
immediately placed in liquid nitrogen and then stored at -80°C. Two biopsies 
were formalin fixed and paraffin-embedded and blocked at Northumbria 
Healthcare NHS Foundation Trust and stored at room temperature. Biopsies 
preserved in Carnoy’s solution (70% ethanol, 30% acetic acid) were kept at 4°C 
for a minimum of 2 hours and maximum of 12 hours and then transferred to 
70% ethanol for long-term storage at 4°C. 
 
Table 1 Biopsy sample collection and storage 
 
Colorectal cancer risk outcome measures and statistical analyses 
In the BFU Study, we will measure similar outcomes to those measured at 
baseline in the BORICC Study. This will include miRNA expression and 
patterns of DNA methylation in rectal mucosal biopsies and in potential 
surrogate tissues, e.g. blood and buccal cells. We will quantify gut-specific and 
systemic inflammatory markers including faecal calprotectin and hsCRP, 
respectively. We will assess colonic crypt cell proliferative state, including 
proliferation rates and the distribution of proliferating cells along the crypt, as a 
marker of CRC risk. We will investigate effects of ageing and of lifestyle factors 
such as obesity on mitochondrial function, as well as the involvement of the 
mitochondria in CRC risk. We will characterise the faecal microbiome and 
quantify short-chain fatty acids.  
Relationships between lifestyle factors measured at baseline with markers of 
CRC risk at follow-up (12+ years later) will be investigated longitudinally, as 
well as cross-sectionally at follow-up. Relationships between potential 
predictors measured at baseline e.g. BMI and outcome variables e.g. faecal 
calprotectin will be examined by regression controlling for potential 
confounders such as sex, age, smoking, dietary factors and physical activity.  
We will also investigate relationships between change in lifestyle factors over 
12+ years, such as a change in markers of adiposity, on our outcome 
measures. For example, to test whether change in adiposity over 12+ years is 
associated with faecal calprotectin concentration, we will divide our 
participants into those who gained body weight, those who lost body weight 
and those whose weight was unchanged, with faecal calprotectin as our 
outcome measure, using the ANOVA General Linear Model.  
 
 
  
RESULTS 
Baseline participant characteristics 
A total of 47 participants were recruited to the BFU Study, comprising 37 
initially-healthy participants (originally recruited to the BORICC 1 arm) and 10 
polyp participants (originally recruited to BORICC 2) (Table 2).  All participants 
were Caucasian. Fifty-one percent of participants were females, all of whom 
were post-menopausal. The mean age of participants was 67 years (range 49 
- 79 years). The mean BMI was 28.3kg/m2 and the means of other markers of 
adiposity were above recommended cut-offs for healthy body composition 
(Table 2). Only one participant was a current smoker, with comparable numbers 
of both male and female ex- and non-smokers.  
 
Table 2 Characteristics of BFU Study participants.  
 
The proportion of BFU participants in each BMI category and comparisons with 
data from England acquired from the Health Survey for England 2017 are 
summarised in Table 3. Approximately 38% and 32% of BFU study participants 
were overweight and obese, respectively, which is similar to data for England 
for persons aged 65 – 74 years. In the 2017 Health Survey for England, 
overweight and obesity prevalence increased with age, peaking in the 55 – 64 
age range (HSE, 2018).  Within England, overweight and obesity rates vary by 
region and are greatest in the North of England. In the North East of England, 
37% and 29% of persons aged 16 and over are overweight or obese, 
respectively (HSE, 2018) which is similar to data for the BFU Study participants 
(Table 3). 
 
Table 3 Proportions (%) of participants in each BMI category in the BFU 
Study,  in England and in the North East of England using data from the 
Health Survey for England 2017 (HSE, 2018).  
 
Blood-based phenotypic markers for BFU Study participants are summarised 
in Table 4.  Values were comparable for male and female participants. Almost 
half (19 participants) had hsCRP concentrations ≥2mg/L. For the majority of 
participants, values were within the normal range for the other analytes. All 
participants had 25(OH)D concentrations classified as vitamin D sufficient 
(>25nmol/L) using the UK criteria (NICE, 2016). For vitamin B12, two 
participants (one male and one female) had concentrations below the 
recommended 145pmol/L and one female participant had a vitamin B12 
concentration above the normal range. One female participant had a serum 
folate concentration suggestive of folate deficiency (<3ug/L). PTH 
concentrations were above the recommended value of 6.4pmol/L for six 
participants but none was below 1.1pmol/L. HbA1c concentration was above 
the diabetes cut-off (48 mmol/mol) for 5 participants all of whom were already 
diagnosed with type 2 diabetes. A total of 23 participants had total cholesterol 
concentrations >5 mmol/L and 17 had a total cholesterol to HDL cholesterol 
ratio greater than 4. Two female participants were below, and four were above, 
the recommended guidelines (1.2 – 1.8 mmol/L) for HDL cholesterol. Three and 
eight male participants were below and above, respectively, the reference 
values for males (1.0 – 1.5mmol/L). Nine participants had high non-HDL 
concentrations (≥4.9mmol/L). 
 
Table 4 Blood phenotype markers:  inflammatory, glucose control, lipid 
profile and nutrient status markers  
 
DISCUSSION 
The BFU Study is a 12+ years follow-up of participants in the BORICC Study 
that has been designed to investigate relationships between ageing and 
lifestyle factors, such as diet, adiposity and physical activity, and markers of 
healthy ageing and of CRC risk. We re-recruited 47 of the original 363 BORICC 
Study participants; approximately half of the BFU Study participants were 
female and the mean age of all participants was 67 years. Within the BFU 
Study, 70% of participants were overweight or obese. This is comparable to the 
proportion of overweight and obese persons aged 16 and over in England 
(64%) and in the North East (63%) and slightly lower than the national 
prevalence reported for those aged 65 – 74 (75%) (HSE, 2018).  
 
Our a priori power calculation estimated that we would require 53 participants 
to detect a statistically significant effect of age on FCP, a local marker of 
intestinal inflammation. Although we re-recruited just under this number, this 
power calculation was based on an age difference of 10 years whereas the 
longitudinal aspect of this study was 12+ years. In addition, the original power 
calculation was based on cross-sectional data and, since this is a longitudinal 
study in which we will make within-participant comparisons over time, it is likely 
that we will have greater power to detect effects. 
 
Study Implications 
Samples and data from the BFU Study will be used to investigate the 
mechanisms through which ageing and lifestyle factors, particularly diet, 
physical activity and adiposity, influence markers of large bowel health and 
CRC risk and of healthy ageing (primarily musculoskeletal function). We will 
focus on mitochondrial function, epigenetic mechanisms, WNT signalling and 
colonic crypt cell proliferative state in colonocytes and on the intestinal 
microbiome and their short-chain fatty acid metabolites. We will investigate the 
effects of lifestyle measured at baseline, particularly diet, adiposity and physical 
activity, on biomarkers of CRC risk 12+ years later and also examine these 
cross-sectionally in the BFU Study. Understanding the underlying mechanisms 
through which protective or detrimental effects of lifestyle factors are achieved 
could lead to more effective early prevention strategies and lifestyle 
interventions. 
 
We will also investigate whether these ageing and lifestyle-related markers of 
CRC risk can be detected in surrogate tissues, such as in blood or buccal cells, 
and so reduce the need for invasively-collected biopsies from the large bowel, 
in the future. The ability to make these biomarker measurements in surrogate 
tissues will i) make it easier for participants in studies, ii) lower the costs for 
research by avoiding the need for expensive investigations of the large bowel 
by specialist doctors and iii) speed up the process of biomarker measurement.  
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 Table 1 Biopsy sample collection and storage 
Sample processing/storage Number of biopsies 
Snap-frozen 4 
RNAlater® (Ambion, USA) 3 
Formalin-fixed paraffin-
embedded (FFPE) 
2 
Carnoy’s solution 1 
 
  
Table 2 Characteristics of BFU Study participants.  
 
Data are presented as means and ranges are in brackets. For smoking status, 
data are presented as number of participants and proportion in brackets (%). 
  
 
All Males Females 
N 47 23 24 
Age (years) 66.7 (49 – 79) 66.3 (49 – 78) 67.2 (52 – 79) 
Menopause status - N/A Post-
menopausal 
BMI (kg/m2) 28.3 
(18.9 – 39.3) 
28.8 
(18.9 – 39.3) 
27.8 
(21 – 39) 
Weight (kg) 81.5 
(56.8 – 124.5) 
91.4 
(60 – 124.5) 
72 
(56.8 – 107.5) 
Body fat (%) 34.2 
(10.9 – 46.2) 
29.7 
(10.9 – 41.2) 
38.6 
(28.9 – 46.2) 
Waist 
circumference (cm) 
96.5 
(72.7 – 137.7) 
102.4 
(74.8 – 137.7) 
80.3 
(72.7 – 115.5) 
Hip circumference 
(cm) 
105 
(90.3 – 136.8) 
106.3 
(90.3 – 136.8) 
103.7 
(92.9 – 128.5) 
Smoking status 
Current smokers 
Ex-smokers 
Non-smokers 
 
1 (2) 
22 (47) 
24 (51) 
 
1 (4) 
11 (48) 
11 (48) 
 
0 (0) 
11 (46) 
13 (54) 
Table 3 Proportions (%) of participants in each BMI category in the BFU 
Study,  in England and in the North East of England using data from the 
Health Survey for England 2017 (HSE, 2018).  
 
BMI category BFU Study 
England 
(persons 
aged 16 and 
over) 
England 
(persons 
aged 65 – 74) 
North East 
England 
(persons 
aged 16 
and over) 
Underweight 0.0 2.0 1.0 2.0 
Normal weight 29.8 34.0 24.0 32.0 
Overweight 38.3 36.0 43.0 37.0 
Obese 31.9 29.0 33.0 29.0 
 
  
Table 4 Blood phenotype markers:  inflammatory, glucose control, lipid 
profile and nutrient status markers  
 
Optimal 
values 
Proportion 
of 
participants 
within 
optimal 
range (%) 
All Males Females 
hsCRP 
(mg/L)a 
<2.00 60 
3.41 
(0.838) 
2.43    
(0.524) 
4.35 
(1.55) 
HbA1c 
(mmol/mol) a 
<48.0 89 
40.5 
(1.06) 
40.2 
(1.40) 
40.8 
(1.61) 
Cholesterol 
(mmol/L)a 
<5.0 51 
5.25 
(0.19) 
5.03 
(0.179) 
5.46 
(0.328) 
HDL 
(mmol/L)b 
1.2 – 1.8 (♀) 
1.0 – 1.5 (♂) 
64 
1.50 
(0.058) 
1.41 
(0.097) 
1.60 
(0.0583) 
Total 
cholesterol 
to HDL-C 
ratiob 
<4.0 64 
3.68 
(0.155) 
3.85 
(0.219) 
3.51 
(0.217) 
Non-HDL 
cholesterol 
(mmol/L)b 
<4.9 81 
3.77 
(0.183) 
3.62 
(0.179) 
3.93 
(0.321) 
Serum Folate 
(ug/L)a 
≥3 98 
7.26 
(0.422) 
8.18 
(0.687) 
6.33 
(0.422) 
Vitamin B12 
(pmol/L)a 
145 - 569 94 
284 
(15.9) 
289 
(14.7) 
281 
(27.6) 
Data are presented as means (SEM). an=47. bn=46. 
 
25(OH) 
Vitamin D 
(nmol/L)a 
>25 100 
66.3 
(4.20) 
61.3 
(6.20) 
71.2 
(5.70) 
PTH 
(pmol/L)a 
1.10 – 6.40 87 
4.50 
(0.200) 
4.20 
(0.300) 
4.90 
(0.300) 

Supplementary Material 
Modifications made to the FFQ to include foods consumed frequently in the 
North East of England: 
• Meat and fish category: the option for ‘fish roe, taramasalata’ was 
removed. In addition, ‘curry’ was added as an example for the options 
for ‘beef’, ‘pork’, ‘lamb’, ‘chicken, turkey or other poultry’. 
• Bread and savoury biscuits category: the option for Crispbread was 
removed. Three additional options were added: i) ‘Scones, teacakes, 
crumpets, muffins or croissants’, ii) ‘Pitta bread, naan bread, chapati’ 
and iii) Garlic bread. 
• Potatoes, rice and pasta category: Three additional options were added: 
i) ‘Yorkshire pudding, pancakes, dumplings’, ii) ‘Tinned pasta e.g. 
spaghetti, ravioli, macaroni’ and iii) ‘Super noodles, pot noodles, pot 
savouries’. Furthermore, ‘potato waffles’ were added to the ‘chips’ option 
and ‘cannelloni’ was added to the ‘Lasagne, moussaka’ option. 
• Dairy products and fats: The following four options were added: i) ‘Low 
calorie, low fat salad cream’, ii) ‘Salad cream, mayonnaise’, iii) ‘French 
dressing’ and iv) ‘Other salad dressing’. The option for ‘Very low fat 
spread (less than 30% fat)’ was removed.  
• Sweets and snacks category: The two options of ‘home baked’ and 
‘ready made’ for ‘Cakes’, ‘Buns, pastries’ and ‘Fruit pies, tarts, crumbles’ 
were merged to form one option for each food e.g. ‘Cakes e.g. fruit, 
sponge, sponge pudding’. The option for ‘Sponge puddings’ was 
removed as a separate entity and added to the ‘Cakes’ option. The 
options for ‘Chocolates, single or squares’ and ‘Chocolate snack bars’ 
were merged to produce one option ‘Chocolates (small bar or 0.25lb of 
chocolates).  
• Soups, sauces and spreads category: the following options were added 
to this section i) ‘Tomato based sauces e.g. pasta sauces’, ii) ‘Low 
calorie, low fat salad cream or mayonnaise’, iii) ‘Salad cream, 
mayonnaise’, iv) ‘French dressing’, v) ‘Other salad dressing’, vi) 
‘Chocolate spread, chocolate nut spread’ and vii) ‘Dips e.g. hummus, 
cheese and chive’. The option for ‘Pickles, chutney’ was modified to 
‘Relishes e.g. pickles, chutney, mustard’. ‘Syrup’ was added as a food 
example for the option on ‘Jam, marmalade, honey’. 
• Drinks category: The option for ‘Coffee, decaffeinated’ was removed. 
• Fruit category: Tangerines and clementines were added as examples to 
the ‘Oranges, satsumas, mandarins’ option and figs to the ‘Dried fruit’ 
option. 
• Vegetables category: ‘Mixed vegetables’ were added as an option to this 
category. The ‘Beetroot’ option was modified to ‘Beetroot, radishes’. The 
option for ‘Broccoli, spring greens, kale’ was modified to ‘Broccoli’. 
• Question 5 was modified to include brands for both bread and breakfast 
cereals 
•  ‘Olive oil’ was added as an option to question 6 (What kind of fat did you 
most often use for frying, roasting, grilling, etc?). Further, the option to 
add the type of vegetable oil used was removed. 
• Questions 2, 7, 10, 11, 12 and 15 from the original EPIC Questionnaire 
were removed 
• Additional questions added to the modified FFQ included ‘Do you follow 
a special diet?’ and ‘Over the last year, how often have you eaten 
organic foods?’ 
 
 
 
